Actively Recruiting
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Led by Atom Therapeutics Co., Ltd · Updated on 2026-04-14
20
Participants Needed
1
Research Sites
31 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
CONDITIONS
Official Title
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 to 75 years with clinical diagnosis of gout
- Stable allopurinol therapy once daily for at least 14 days before Day 1
- Normal renal function (Cohort N) or moderate renal impairment (Cohort R)
You will not qualify if you...
- Clinically significant liver impairment
- History of hypersensitivity to allopurinol
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wakefield Clinical Research
Cary, North Carolina, United States, 27560
Actively Recruiting
Research Team
M
MaoE Sun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here